Koen Nieman, MD
Cardiovascular Disease · Stanford, CANPI 1144778143
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Cleerly, Inc. accounts for 69.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $38,582 and has fallen 99.1% since, to $338 in 2025. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $1546.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cleerly, Inc.$32K
- Novartis$11K
- Siemens Medical Solutions USA, Inc.$3K
- Heartflow, Inc.$181
- GE HealthCare$100
Across 39 payments — averaging $12,589 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$212K
- Cleerly, Inc.$186K
- Heartflow, Inc.$92K
- Novartis Pharma AG$1K
What the payments were for
- Consulting fees$26,99958%
- Speaking & faculty fees$12,35027%
- Travel & lodging$2,9416%
- Food & beverage$4,1179%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cleerly, Inc. | 10 | $32,212 |
| Novartis | 6 | $11,207 |
| Siemens Medical Solutions USA, Inc. | 10 | $2,707 |
| Heartflow, Inc. | 3 | $181 |
| GE HealthCare | 1 | $100 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAEOTOM Alpha$296
- Cleerly Ischemia$166
- Cleerly Labs$166
- FFRct$112
- ENTRESTO$103
- LEQVIO$103
How this compares
$46,408 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $27,805 |
| Atorvastatin Calcium | 48 | $956 |
| Metoprolol Succinate | 33 | $404 |
| Carvedilol | 18 | $279 |
| Ezetimibe | 12 | $134 |
| Losartan Potassium | 16 | $93 |
| Rosuvastatin Calcium | 11 | $75 |
| Metoprolol Tartrate | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Wilber SuStanford$1.1M
- Euan AshleyStanford$508K
- Kenneth MahaffeyStanford$447K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.